Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tridihexethyl. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 6/20 | 0.97 |
| ▸ | CHRM3 known ✓ | P20309 | 3/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.97 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.56 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.56 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.56 |
| ▸ | HRH1 | P35367 | 1/20 | 0.56 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.56 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.56 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.56 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tridihexethyl SCHEMBL94230 | 0.99 | CHRM2 (1.00) | CHRM2CHRM1KCNH2CYP2D6CHRM3 | |
| Tridihexethyl SCHEMBL2296006 | 0.99 | CHRM2 (1.00) | CHRM2CHRM1KCNH2CYP2D6CHRM3 | |
| Tridihexethyl SCHEMBL249851 | 0.97 | CHRM2 (0.97) | CHRM2CHRM1KCNH2CYP2D6CHRM3 | |
| SCHEMBL20045514 | 0.82 | CHRM2 (0.71) | CHRM2CHRM1KCNH2CYP2D6CHRM3 | |
| SCHEMBL9910958 | 0.80 | CHRM2 (0.68) | CHRM2CHRM1KCNH2CYP2D6CHRM3 | |
| Tridihexethyl SCHEMBL5824214 | 0.80 | CHRM2 (0.61) | CHRM2CHRM1KCNH2CYP2D6CHRM3 | |
| SCHEMBL2933098 | 0.79 | CHRM2 (0.66) | CHRM2CHRM1KCNH2CYP2D6CHRM3 | |
| SCHEMBL12441787 | 0.79 | CHRM2 (0.66) | CHRM2CHRM1KCNH2CYP2D6CHRM3 | |
| SCHEMBL10516359 | 0.76 | CHRM2 (0.64) | CHRM2CHRM1KCNH2CYP2D6CHRM3 | |
| SCHEMBL10392382 | 0.76 | CHRM2 (0.64) | CHRM2CHRM1KCNH2CYP2D6CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1922 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220008334-A1 | GASTRIC RETENTIVE DEVICES | CLEXIO BIOSCIENCES LTD. (IL) | 2022-01-13 | — | — | US | claimed |
| US-11147766-B2 | Gastric retentive devices | CLEXIO BIOSCIENCES LTD. (IL) | 2021-10-19 | — | — | US | claimed |
| US-9649093-B2 | Cavity-filling biopsy site markers | SENORX, INC. (US) | 2017-05-16 | — | — | US | claimed |
| US-20170112829-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-04-27 | — | — | US | claimed |
| US-20160120510-A1 | CAVITY-FILLING BIOPSY SITE MARKERS | SENORX, INC. | 2016-05-05 | — | — | US | claimed |
| US-8679535-B2 | Sustained release matrix systems for highly soluble drugs | ENDO PHARMACEUTICALS INC. (US) | 2014-03-25 | — | — | US | claimed |
| US-20110052723-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-03-03 | — | — | US | claimed |
| WO-2010101649-A2 | SIGMA 1 RECEPTOR INHIBITION AS A NOVEL THERAPEUTICAL APPROACH AGAINST HEPATITIS C VIRUS INFECTION | GASTAMINZA PABLO (US) | 2010-09-10 | — | — | WO | claimed |
| US-20100130544-A1 | USE OF PARASYMPATHOLYTIC SUBSTANCES TO ENHANCE AND ACCELERATE STEM CELL DIFFERENTIATION, RELATED METHODS AND COMPOSITIONS | UNIVERSITA' DEGLI STUDI DI TORINO (IT) | 2010-05-27 | — | — | US | claimed |
| EP-2090311-A1 | Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-08-19 | — | — | EP | claimed |
| US-20050234336-A1 | Apparatus and method for marking tissue | GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT | 2005-10-20 | — | — | US | claimed |
| US-6862470-B2 | Cavity-filling biopsy site markers | SENORX, INC. (US) | 2005-03-01 | — | — | US | claimed |
| US-20050037374-A1 | Combined nanotechnology and sensor technologies for simultaneous diagnosis and treatment | FLORIDA, UNIVERSITY OF | 2005-02-17 | — | — | US | claimed |
| EP-1494721-A2 | CAVITY FILLING BIOPSY SITE MARKER | Senorx, Inc. (US) | 2005-01-12 | — | — | EP | claimed |
| WO-2005000266-A2 | LIPOSOMAL FORMULATIONS COMPRISING A COMBINATION OF TWO OR MORE ACTIVE AGENTS | NEOPHARM, INC. (US) | 2005-01-06 | — | — | WO | claimed |
| WO-2003089012-A2 | CAVITY FILLING BIOPSY SITE MARKER | SENORX, INC. (US) | 2003-10-30 | — | — | WO | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| US-20020188196-A1 | Cavity-filling biopsy site markers | SENORX, INC. | 2002-12-12 | — | — | US | claimed |
| US-5023088-A | Drug delivery dispenser | ALZA CORPORATION (US) | 1991-06-11 | — | — | US | claimed |
| US-5008111-A | Pretreating skin with anticholinergic quaternary ammonium salt to suppress perspiration | SCHERING CORPORATION (US) | 1991-04-16 | — | — | US | claimed |